We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.
Building a leading microbiome company in oncology
We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.
Corporate profile
Press Releases

November 13, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

November 9, 2023: MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

November 6, 2023: MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
Posters

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe

A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial

Robust Machine Learning (ML) approach for Screening Microbiome Ecosystem Therapies (MET) Drug Candidates in combination with Immune Checkpoint Inhibitors
